Dermatologic emergencies

American Family Physician

Volumn 82, Issue 7, 2010, Pages 773-780

  Usatine, Richard P ^a   Sandy, Natasha ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CHLORAMPHENICOL; DOXYCYCLINE; IMMUNOGLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULFANILAMIDE DERIVATIVE; TETRACYCLINE; ANTIINFECTIVE AGENT;

ARTICLE; CAUSAL ATTRIBUTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; DIAGNOSTIC IMAGING; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ECHOGRAPHY; FLUID RESUSCITATION; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE TEST; LABORATORY TEST; NECROTIZING FASCIITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PUNCH BIOPSY; ROCKY MOUNTAIN SPOTTED FEVER; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; WOUND CARE; EMERGENCY; FEMALE; MALE; REVIEW;

ANTI-BACTERIAL AGENTS; EMERGENCIES; EPIDERMAL NECROLYSIS, TOXIC; FASCIITIS, NECROTIZING; FEMALE; HUMANS; MALE; ROCKY MOUNTAIN SPOTTED FEVER; STEVENS-JOHNSON SYNDROME;

EID: 78149486851     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. American Academy of Dermatology. Cutaneous anthrax management algorithm. http://www.aad.org/members/disaster/bioterrorism/bio_anthrax_cutaneous.html. Accessed July 5, 2009.
2. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense [published correction appears in JAMA. 2000;283(15):1963]. JAMA. 1999;281(18):1735-1745.
3. Usatine R, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. The Color Atlas of Family Medicine. New York, NY: McGraw-Hill; 2009.
4. Stevens DL, Bisno AL, Chambers HF, et al.; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections [published corrections appear in Clin Infect Dis. 2005;41(12):1830 and Clin Infect Dis. 2006;42(8):1219]. Clin Infect Dis. 2005;41(10):1373-1406.
5. Centers for Disease Control and Prevention. Group A streptococcal (GAS) disease. http://www.cdc.gov/ncidod/dbmd/diseaseinfo/groupastreptococcal_t.htm. Accessed July 1, 2009.
6. Simonart T, Simonart JM, Derdelinckx I, et al. Value of standard laboratory tests for the early recognition of group A beta-hemolytic streptococcal necrotizing fasciitis. Clin Infect Dis. 2001;32(1):E9-E12.
7. Centers for Disease Control and Prevention. Tickborne rickettsial diseases: Rocky Mountain spotted fever. http://www.cdc.gov/ticks/diseases/rocky_mountain_spotted_fever/. Accessed June 30, 2009.
8. Chapman AS, Bakken JS, Folk SM, et al.; Tickborne Rickettsial Diseases Working Group; CDC. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis-United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep. 2006;55(RR-4):1-27.
9. Wolff K, Johnson RA, Fitzpatrick TB. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology. 5th ed. New York, NY: McGraw-Hill; 2005:756-758.
10. Fromowitz JS, Ramos-Caro FA, Flowers FP; University of Florida. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnsonsyndrome. Int J Dermatol. 2007;46(10):1092-1094.
11. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58(1):33-40.
12. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg. 1986;204(5):503-512.
13. O'Reilly M, Paddock C, Elchos B, Goddard J, Childs J, Currie M. Physician knowledge of the diagnosis and management of Rocky Mountain spotted fever: Mississippi, 2002. Ann N Y Acad Sci. 2003;990:295-301.
14. Byrd RP Jr, Vasquez J, Roy TM. Respiratory manifestations of tick-borne diseases in the Southeastern United States. South Med J. 1997;90(1):1-4.
15. Holman RC, McQuiston JH, Haberling DL, Cheek JE. Increasing incidence of Rocky Mountain spotted fever among the American Indian population in the United States. Am J Trop Med Hyg. 2009;80(4):601-605.
16. Weber D, Cohen MS, Rutala WA. The acutely ill patient with fever and rash. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, Pa.: Churchill Livingstone; 2005:729-46.
17. Cunha BA. Clinical features of Rocky Mountain spotted fever. Lancet Infect Dis. 2008;8(3):143-144.
18. Chen LF, Sexton DJ. What's new in Rocky Mountain spotted fever? Infect Dis Clin North Am. 2008;22(3):415-432.
19. Dufel S, Martino M. Simple cellulitis or a more serious infection? J Fam Pract. 2006;55(5):396-400.
20. James WD, Berger TG, Elston DM, Odom RB. Andrews' Diseases of the Skin: Clinical Dermatology. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2006.
21. Cheng NC, Chang SC, Kuo YS, Wang JL, Tang YB. Necrotizing fasciitis caused by methicillin-resistant Staphylococcus aureus resulting in death. A report of three cases. J Bone Joint Surg Am. 2006;88(5):1107-1110.
22. Krenk L, Nielsen HU, Christensen ME. Necrotizing fasciitis in the head and neck region: an analysis of standard treatment effectiveness. Eur Arch Otorhinolaryngol. 2007;264(8):917-922.
23. Parrillo SJ. Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Allergy Asthma Rep. 2007;7(4):243-247.